TEMPUS CAPITAL INC.

Tempus AI said it signed $1.1 billion in sealed data contracts with 70 customers in 2025, including major life-sciences firms such as AstraZeneca, Pfizer, Merck and Abbvie. The company reported revenue retention around 126% and called 2025 a record year for its Data and Applications business. Shares rose as much as 15% intraday and closed up 4.51% at $69.26. Tempus AI plans to finalize and report full 2025 financial results on an earnings call in February 2026. » Altro su finance.yahoo.com

Tempus AI guided FY25 revenue to $1.25–$1.26 billion (about 81% YoY) and expects roughly $1.55 billion in FY26 revenue, valuing the company at ~9.16x 2026 sales. Recent catalysts include FDA clearance for its xR IVD product and the $81 million acquisition of Paige, which expand addressable markets and AI pathology capabilities. Analysts note strong revenue visibility and execution, while valuation appears supported by forward growth despite a trailing P/E around 41.5 and elevated share performance since April. » Altro su finance.yahoo.com

Tempus AI stock climbed to an all-time high of $98.14, bringing market capitalization to about $16.16 billion. Analyst price targets range from $60 to $100; Guggenheim raised its target to $95 and H.C. Wainwright to $98. Tempus recorded revenue growth of 59.84% over the last twelve months and a 1-year performance of +96.54%. The company received FDA 510(k) clearance for the RNA-based diagnostic Tempus xR IVD and expanded its CARE program for breast cancer screening. » Altro su de.investing.com